Catheter Ablation as Treatment for Atrial Fibrillation
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage for transcatheter catheter ablation (radiofrequency, cryoablation, and pulsed field ablation) as treatment for symptomatic atrial fibrillation for Blue Cross Blue Shield of Kansas members, including indications, repeat procedures, and investigational uses.
CPT code 93651 was removed effective 12-31-2012.
New CPT codes 93653, 93654, 93655, 93656, and 93657 were added effective 01-01-2013.
ICD-10 diagnosis codes were added to the coding section (Effective October 1, 2014).
Added 'or pulse field ablation' to the policy description.
Added CPT code C1733 to the coding section.
Revised policy language to permit radiofrequency ablation, cryoablation, and pulse field ablation as medically necessary in specified AF cases.
Coverage Criteria and Evidence Basis
Medically necessary indications
Covered when ANY of the following are met
Applicable to transcatheter radiofrequency ablation, cryoablation, or pulsed field ablation.
Allows ablation as an alternative to AV nodal ablation/pacing.
Policy permits ablation (RFA/cryoablation/PFA) as initial therapy in this specific population.
Refer to Policy Guidelines regarding scope, timing, and frequency of repeat procedures.
Evidence-supported indications
Covered when ALL of the following are met
Evidence from systematic reviews and RCTs demonstrates improved maintenance of sinus rhythm with catheter ablation versus medication (see systematic reviews and RCT summaries).
Multiple trials included patients who failed antiarrhythmic drugs; failure of medical therapy is a key inclusion criterion in the evidence base.
Initial ablation coverage criteria
Covered when ALL of the following are met
Rate control agents include calcium channel blockers, beta-blockers, digoxin; rhythm-control medications include dronedarone and amiodarone.
Trials and observational studies reported benefit for these techniques in patients who failed antiarrhythmic drugs.
Repeat procedure criteria
Repeat procedures
Studies reported repeat-procedure rates ranging from ~8% to 32%; repeat ablation improved long-term freedom from AF in RCTs of reablation versus drug therapy.
Repeat procedures
Considered when
Evidence shows variability in timing and indications for re-ablation and uncertainty exists regarding optimal timing and whether medications should be tried prior to repeat procedures.
Individuals with Symptomatic AF and Congestive Heart Failure Who Have Failed Rate Control and Antiarrhythmic Drugs
Covered when ALL of the following are met for individuals with heart failure:
Systematic reviews and RCTs suggest catheter ablation improves LVEF, symptoms, exercise tolerance, and quality of life in selected heart failure populations.
Individuals with Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Covered when ALL of the following are met for individuals with recurrent paroxysmal AF:
Evidence from multiple RCTs supports improved arrhythmia outcomes and quality-of-life measures with first-line cryoablation or RFA in selected patients.
Evidence summaries relevant to coverage
Evidence-based findings relevant to coverage decisions
Findings support consideration of first-line ablation in selected patients with paroxysmal AF.
Evidence includes multicenter RCTs and systematic reviews.
Consistent benefit for paroxysmal AF across several RCTs.
Long-term multicenter RCT evidence with mixed primary endpoint results but secondary benefits.
Clinical input supported that PFA provides clinically meaningful improvement for selected patients who have failed medical management.
Evidence-based coverage rationale
Summary conclusions from randomized and nonrandomized studies and clinical input:
Limitations include predominantly 1-year follow-up and limited participant diversity in trials.
Indications (Pulsed field and general catheter ablation)
Covered when criteria are met and in alignment with guideline recommendations
ACC/AHA guidelines state catheter ablation is useful in patients with symptomatic AF when antiarrhythmic drugs are ineffective, contraindicated, not tolerated, or not preferred; first-line ablation may be appropriate in selected younger patients with symptomatic paroxysmal AF who desire rhythm control.
Medically necessary — truncated
Medically necessary when stated clinical criteria are met (full criteria text not present in this excerpt).
The full qualifying conditions are referenced in the document but are truncated in these chunks.
Covered with criteria
Policy indication wording revised to require medication trial failure
Revision explicitly added requirement that indications in Item A have failed adequate trials of antiarrhythmic medications.
Medically Necessary Indications
Covered when ONE of the following is met (policy-level summary as reflected in revisions):
Reflects policy revisions permitting initial ablation in selected symptomatic paroxysmal AF patients.
Reflects Item A revisions and heart-failure–specific indication.
Reflects Item B/C revisions clarifying repeat procedures.
Transcatheter radiofrequency ablation, cryoablation, or pulse field ablation performed for atrial fibrillation that does not meet the policy’s listed indications is classified as experimental / investigational and is not covered under this policy.
The evidence base does not generally support ablation as routine first‑line therapy except in the specific population identified in the policy. Meta-analyses and trials informed coverage for patients who had failed antiarrhythmic drug therapy; the policy permits ablation as an initial treatment only for recurrent symptomatic paroxysmal atrial fibrillation when a rhythm‑control strategy is desired.
No additional explicit exclusions are enumerated in the provided excerpts. However, the document notes that study selection excluded overlapping populations and that coverage determinations (including whether a listed code is payable) depend on the member’s contract benefits and whether the procedure is performed according to the policy.
A literature search identified no published evidence supporting the use of cryoablation specifically for individuals with atrial fibrillation and heart failure, indicating an evidence gap for that modality in this population.
Study selection principles excluded studies with duplicative or overlapping populations; the review prioritized randomized controlled trials and prospective comparative studies to avoid double‑counting and to ensure methodological credibility.
Key randomized trials and device studies had limitations that affect generalizability: follow-up in many RCTs was limited to 1 year, and several trials enrolled predominantly White participants, raising concerns about representation and applicability to more diverse or treatment‑refractory populations.
The coding entries in this policy are provided for informational purposes only. Inclusion of CPT/HCPCS codes does not by itself establish member coverage or reimbursement; actual coverage is determined by whether the procedure is performed in accordance with the policy and by the member’s contract benefits.
Within the provided document excerpts there are no explicit procedural exclusions listed beyond the general statement that procedures not meeting the policy criteria are considered investigational.
Several chunks in the revisions and coding sections reiterate that the policy does not list additional explicit exclusions in these excerpts; instead, treatments outside the stated indications are treated as investigational and subject to noncoverage.
Historically, the policy has used investigational language to designate ablation modalities when used outside the specified indications. Prior versions explicitly described transcatheter cryoablation and other modalities as experimental / investigational for non‑specified or otherwise unsupported indications.
When the clinical criteria in the Policy section are not met, transcatheter ablation for atrial fibrillation is considered not medically necessary (i.e., not covered). This applies to any modality used outside the listed indications.
There is insufficient trial evidence in the provided excerpts to support ablation for indications that were not studied in the randomized trials (for example, asymptomatic AF without prior medical therapy). Use of ablation for such unstudied indications therefore lacks trial support in this review.
The excerpts do not enumerate a list of specific conditions deemed not medically necessary beyond the general rule that procedures outside the policy criteria are investigational; adverse event rates and high repeat‑procedure rates are noted considerations when evaluating appropriateness.
In the advanced heart failure population studied in the AMICA trial, catheter ablation did not demonstrate benefit at 1 year and the trial was terminated early for futility, indicating limited or no demonstrated advantage in that specific high‑risk cohort.
Some excerpts reiterate that no additional explicit not‑medically‑necessary conditions are listed in the provided text; the policy instead defines covered indications and treats other uses as investigational.
Durability of benefit beyond 1 year is not established by the cited randomized controlled trials; many trials used 12‑month follow‑up, which limits conclusions about long‑term effectiveness.
The provided chunks do not specify additional procedural or clinical exclusions beyond those already noted elsewhere in this policy excerpt.
These specific excerpts do not explicitly state further exclusion criteria; policy language focuses on defining covered indications and treating other uses as investigational.
A historical note in the revisions log documents that transcatheter cryoablation and other modalities were previously listed as investigational when used outside the specified indications; current policy language has been updated over time to clarify allowable modalities and indications.
Procedure and Diagnosis Codes
| Current Procedural Terminology | Referenced; CPT codes apply as appropriate (document cites CPT copyright). |
| affected codes | The document references coding and effective dates for professional and institutional sides but specific CPT/HCPCS/ICD-10 codes are not listed in these chunks. |
| 93653 | Added CPT code (document lists as new CPT added effective 01-01-2013) |
| 93654 | Added CPT code (document lists as new CPT added effective 01-01-2013) |
| 93655 | Added CPT code (document lists as new CPT added effective 01-01-2013) |
| 93656 | Added CPT code (document lists as new CPT added effective 01-01-2013) |
| 93657 | Added CPT code (document lists as new CPT added effective 01-01-2013) |
| 93651 | Removed CPT code (Effective 12-31-2012) |
| 93651 | CPT code removed (Effective 12-31-2012) |
| ICD-10 (group) | ICD-10 diagnosis codes were added to the coding section effective October 1, 2014 (specific ICD-10 codes not listed in this chunk) |
| 93651 | Previously listed CPT code removed (Effective 12-31-2012) |
| 93651 | Removed CPT code (Effective 12-31-2012) |
| 93651 | Previously used CPT code — removed (Effective 12-31-2012) |
| ICD-10 | ICD-10 Diagnosis codes were added to the coding section (effective October 1, 2014); specific ICD-10 codes are not listed in this chunk. |
| 93653 | CPT code added (policy lists 93653 as added effective 01-01-2013) |
| 93654 | CPT code added (policy lists 93654 as added effective 01-01-2013) |
| 93655 | CPT code added (policy lists 93655 as added effective 01-01-2013) |
| 93656 | CPT code added (policy lists 93656 as added effective 01-01-2013) |
| 93657 | CPT code added (policy lists 93657 as added effective 01-01-2013) |
| 93651 | CPT code removed (Effective 12-31-2012) |
| ICD-10 (various) | ICD-10 Diagnosis codes were added to the Coding section (Effective October 1, 2014) |
| 93651 | CPT code removed (Effective 12-31-2012) |
| I48.0 | ICD-10 code added (historical entry) |
| I48.11 | ICD-10 code added (historical entry) |
| I48.19 | ICD-10 code added (historical entry) |
| I48.20 | ICD-10 code added (historical entry) |
| I48.21 | ICD-10 code added (historical entry) |
Authorization, Documentation, and Billing Guidance
Verify eligibility and benefits
Verify member benefits and contract language prior to scheduling or requesting authorization; contact Blue Cross and Blue Shield of Kansas Customer Service to confirm coverage for catheter ablation procedures.
- Coverage depends on the member's contract and plan-specific provisions.
- Inclusion of codes in the policy does not guarantee coverage; verify benefits at time of service.
Prior authorization to confirm indications
Obtain prior authorization when seeking coverage for ablation to confirm the patient meets trial‑based indications (e.g., symptomatic paroxysmal or persistent AF who failed antiarrhythmic drugs) and to align with RCT populations used in the evidence base.
- Prior authorization is typically appropriate to confirm that patients meet the trial criteria used in RCTs (symptomatic paroxysmal or persistent AF after failed antiarrhythmics).
- Documentation supporting prior therapy and indication should be available for review.
Prior authorization for ablation — confirm symptomatic status and prior therapy
Request prior authorization that documents the patient is symptomatic and has failed appropriate rate‑control and/or antiarrhythmic drug therapy (or has documented intolerance/contraindication) when indicated; include prior therapy details.
- Policy requires that indications have failed to respond to adequate trials of antiarrhythmic medications or show intolerance/contraindication (Item A).
- For AF with heart failure, document failure of rate control and antiarrhythmic drugs as applicable.
Procedure type and treatment intent must be specified
Specify the planned procedure type and treatment intent on authorization requests—state whether the proposed therapy is radiofrequency ablation (RFA), cryoablation, or pulsed field ablation (PFA) and whether it is intended as initial rhythm‑control therapy or after failed medical management.
- Policy Items A–C include RFA, cryoablation, and PFA as covered modalities when criteria are met.
- Prior authorization should reflect whether ablation is initial therapy for recurrent symptomatic paroxysmal AF or therapy after failed medical management.
Prior authorization: document indication and prior antiarrhythmic therapy
When requesting prior authorization, provide documentation of symptomatic paroxysmal or persistent AF and records of prior failure or intolerance of antiarrhythmic medications (or contraindication) as required by the policy.
- Policy wording was revised to require failure of adequate trials of antiarrhythmic medications for the listed indications.
- Authorization should request prior antiarrhythmic drug therapy status and intolerance/contraindication documentation.
Coding listed — medical necessity contingent on policy compliance
Listed CPT/HCPCS codes in the policy are informational; medical necessity for listed codes is contingent on performing the procedure according to the Policy section and member benefits.
- Inclusion or exclusion of a code does not imply member coverage or reimbursement.
- Codes listed are medically necessary ONLY if the procedure is performed according to the Policy section.
Check coding effective‑date notes for billing distinctions
Follow the coding effective‑date notes in the policy and be aware of professional/institutional date distinctions when preparing authorizations or claims.
- Policy documents multiple historical coding updates and corrected effective dates for professional and institutional sides.
- Ensure effective‑date considerations are applied when submitting claims or authorization requests.
Do not use removed CPT 93651 for claims (removed 12‑31‑2012)
Do not bill with obsolete CPT 93651; the policy records removal of CPT 93651 effective 12‑31‑2012—use current CPTs for claims and authorizations.
- CPT code 93651 was removed effective 12‑31‑2012.
- Claims submitted using removed CPT 93651 after its removal date may be denied.
Bill and authorize using CPTs 93653–93657 (effective 01‑01‑2013)
Use the updated CPT codes 93653–93657 (effective 01‑01‑2013) when requesting prior authorization and submitting claims for catheter ablation procedures.
Use current CPTs for authorization/claims and omit removed codes
Ensure authorization requests and claims list the current CPT codes affected by the policy (93653–93657) and do not include removed codes; coding updates can affect prior authorization and claim adjudication.
- The document lists current CPT codes 93653–93657 and records removal of CPT 93651.
- Policy revisions note that CPT code updates over time may affect prior authorization and claim processing.
Document prior adequate antiarrhythmic medication trials
Policy revisions require documentation that specified indications have failed adequate trials of antiarrhythmic medications prior to ablation; include medication trial details or documented intolerance/contraindication when submitting for coverage.
- Item A now specifies indications that have failed to respond to adequate trials of antiarrhythmic medications.
- Verify and document prior medication trials or intolerance/contraindication in the record for authorization.
Document prior rate‑ and rhythm‑control medication trials
Expect step‑through medical therapy context: document prior use of rate‑control agents (calcium channel blockers, beta‑blockers, digoxin) and rhythm‑control agents (e.g., dronedarone, amiodarone) as applicable when relevant to the indication.
- Comparators and trial populations assume prior medication management including rate or rhythm control.
- Policy populations (e.g., AF with heart failure) expect failure of rate control and antiarrhythmic drugs.
If PFA is planned, state modality and prior medical management
Pulsed field ablation (PFA) is included in the policy as an alternative to thermal ablation for patients who have failed medical management; prior authorization should note whether PFA is planned and document relevant prior medical therapy.
- PFA is evaluated as an alternative for symptomatic paroxysmal or persistent AF who have failed medical management.
- Clinical input supports PFA in patients who have failed antiarrhythmic drugs; authorization should list modality.
Include specified clinical documentation in prior authorization
Provide required clinical documentation with authorization: AF type (paroxysmal or persistent), symptomatic status, prior antiarrhythmic and rate‑control trials (or intolerance/contraindication), prior ablation history if applicable, and planned ablation modality (RFA, cryo, or PFA).
- Documentation should capture indication, prior antiarrhythmic and rate‑control trials, prior cardioversions or AV nodal ablation considerations, and planned ablation technology.
- Policy Guidelines note procedure codes are medically necessary only if procedure is performed according to the Policy section.
Do not seek coverage for indications outside policy criteria (may be denied)
Procedures that do not meet the policy's listed medically necessary criteria are considered experimental/investigational and are subject to denial; do not request authorization for indications outside those specified without supporting documentation.
- Item D states ablation to treat AF that does not meet the criteria is experimental/investigational.
- The policy explicitly designates treatments outside the outlined criteria as investigational and may be denied.
Risk of denial for incomplete prior‑procedure or therapy documentation
Be aware that lack of documentation about prior ablation strategy, prior therapy failure, or high complication/ repeat‑procedure rates may trigger denials; ensure complete records to support medical necessity.
- Repeat procedures are common; missing prior procedure details can lead to denials.
- Large database studies report major adverse event rates of 4–9%, which may influence adjudication if complications or candidate selection are unclear.
Evidence limitations that may affect coverage decisions
Note evidence limitations may affect coverage determinations—trial follow‑up in many RCTs is limited to ~1 year and trial populations lacked diversity; these factors can influence adjudication in borderline cases.
- Study follow‑up durations were limited to 1 year, limiting durability conclusions.
- Trials included primarily White participants and had limited reporting on treatment‑refractory populations; this may affect coverage decisions.
Claims risk if using removed CPT 93651 after removal date
Claims submitted using removed CPT 93651 after its removal date (12‑31‑2012) may be denied; update billing systems and historic claims submissions to use current CPT codes.
- Policy repeatedly documents removal of CPT 93651 effective 12‑31‑2012.
- Claims using 93651 after its removal date risk denial per policy statements.
Background, Definitions, and Terminology
Atrial fibrillation is the most common cardiac arrhythmia; focal triggers frequently originate at the pulmonary vein–left atrial junction. Catheter ablation targets these triggers or the arrhythmogenic substrate to restore sinus rhythm or improve response to medical management.
Policy Revision History and Changes
CPT code 93651 was removed from the policy coding section (effective 12-31-2012).
New CPT codes 93653, 93654, 93655, 93656, and 93657 were added to the policy coding section (effective 01-01-2013).
ICD-10 diagnosis codes were added to the coding section effective October 1, 2014 (policy records addition of ICD-10 codes).
Policy record indicates removal of ICD-10 codes from the coding section (document notes 'Removed ICD-10 Codes' on 04-23-2025).
CPT code C1733 was added to the coding section (recorded effective 06-15-2026) and 'pulse field ablation' was explicitly added to the Description/Policy sections prior to posting; coding section updated accordingly.
The document records multiple historical editorial and coding updates over time, including descriptive and reference section edits and several coding revisions that reflect evolving procedure coding and policy clarification.
The revisions log documents removal of CPT code 93651 effective 12-31-2012; providers should avoid using this obsolete code for claims after that date.
New CPT codes 93653–93657 were added effective 01-01-2013 and are reflected in the policy’s coding section as the current procedure codes for AF catheter ablation.
ICD‑10 diagnosis codes were added to the coding section effective October 1, 2014, and the policy includes guidance to use appropriate ICD‑10 codes on or after that date.
A recent revision entry shows that CPT code C1733 was added to the coding section and that pulse field ablation was explicitly added to the Description and Policy sections (revision effective 06-15-2026 in the log).
Policy Items A–D and guideline language have been revised iteratively to clarify indications, permit repeat procedures, and update investigational statements; these revisions reflect refinement of coverage for radiofrequency ablation, cryoablation, and pulse field ablation in specified AF cases.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.